期刊文献+

基质金属蛋白酶-2在低氧性肺动脉高压大鼠肺血管中的表达及辛伐他汀对其影响

Expression of Matrix Metalloproteinase-2 in Pulmonary Arteries of Rats with Hypoxic Pulmonary Hypertension and Effect of Simvastatin
下载PDF
导出
摘要 目的观察基质金属蛋白酶-2(MMP-2)在低氧性肺动脉高压大鼠肺血管中的表达,及辛伐他汀对其表达的调节作用。方法采用随机分组方法将30只雄性SD大鼠分为对照组、低氧组和预防组,每组10只,低氧组和预防组给予低氧处理,建立大鼠低氧性肺动脉高压模型,且预防组于低氧前给予辛伐他汀灌胃,对照组不做任何处理。3周后观察大鼠平均肺动脉压(mPAP)、右心室肥厚指数即右心室/(左心室+室间隔)和肺血管形态学指标的变化。采用免疫组织化学染色方法检测大鼠肺小动脉MMP-2表达。结果低氧组大鼠mPAP、右心室肥厚指数、肺血管形态学指标和肺小动脉MMP-2染色强度均高于对照组,差异有统计学意义(P<0.01);而预防组上述指标低于低氧组,差异有统计学意义(P<0.01)。结论 MMP-2在低氧性肺动脉高压大鼠肺血管中的表达增加,辛伐他汀可抑制其表达,预防低氧性肺动脉高压的形成。 Objective To observe the expression of matrix metalloproteinase-2(MMP-2) in hypoxic hypertension rats pneumoangiogram and the modulation of simvastatin.Methods Randomly divide 30 male SD rats were randomly divided into control group,hypoxia group and prevention group,with 10 rats in each group,hypoxia group and prevention group was given the hypoxia treatment,to establish the model of hypoxic pulmonary hypertension in rats,and the prevention group in the hypoxia of simvastatin orally,the control group without any treatment.The mean pulmonary pressure(mPAP),right ventricular hypertrophy index-right ventricle /(left ventricle plus septum),and the pneumoangiogram morphological index of rat were observed after three weeks.The expressing level of MMP-2 in pulmonary artererioles were measured by immunohistochemistry.Results In hypoxic group the mPAP,right ventricular hypertrophy index,and the pneumoangiogram morphological index all were higer than that in control group,the difference was statistically significant(P &lt; 0.01);While in preventive group these index decreased obviously compared with that in hypoxic group,The difference was statistically significant(P &lt; 0.01).Conclusion Increased expression of MMP-2 in pulmonary arteries of rats with hypoxic pulmonary hypertension,and simvastatin can prevent hypoxic pulmonary hypertension through inhibiting expression of MMP-2.
出处 《实用心脑肺血管病杂志》 2013年第8期37-39,共3页 Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
关键词 缺氧 高血压 肺性 辛伐他汀 基质金属蛋白酶2 Anoxia Hypertension,pulmonary Simvastatin Matrix metalloproteinase 2
  • 相关文献

参考文献11

  • 1Schumann C, Lepper PM, Frank H, et al. Circulating biomarker of tissue remodelling in pulmonary hypertension [J]. Biomarker, 2010, 15 (6): 523-532.
  • 2Hassoun PM. Deciphering the " matrix" in pulmonary vascular remode- ling [J]. Eur Respir J, 2005, 25 (5): 778-779.
  • 3Lee JH, Lee DS, Kim EK, et al. Simvsatatin in hibits cigarette smok- ing- induced emphysema and pulmonary hypertension in rat lungs [ J]. Am J Respir CritCare Med, 2005, 172 (8) : 987 -993.
  • 4夏秀琼,程德云,苏巧俐,陈小菊,杨莉.辛伐他汀对大鼠低氧性肺动脉高压的作用[J].中华结核和呼吸杂志,2007,30(5):386-388. 被引量:10
  • 5Maxova H, Novotnd J, Vajner L, et al. In vitro hypoxia increases pro- duction of matrix metalloproteinases and tryptase in isolated rat lung mast cells[J]. Physiol Res, 2008, 57 (6): 903-910.
  • 6Paddenberg R, Faulhammer P, Goldenberg A, et al. Hypoxia - in- ducecl increase of endostatin in runrine aorta and lung [J]. Histochem Cell Binl, 2006, 125 (5) : 497 -508.
  • 7Frisdal E, Gest V, Vieillard- Baron A, et al. Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension [ J]. Eur Respir J, 2001, 18 (5): 838-845.
  • 8Li M, Li Z, Sun X. Statins suppress MMP2 secretion via inactivation of RhoA/ROC pathway in pulmonary vascular smooth muscles cells [ J]. Eur J Phm'm~ol, 2008, 591 (1/3) : 219 - 223.
  • 9Murata T, Kinoshita K, Hori M, et al. Statin protects endothelial ni- tric oxide synthase activity in hypoxia - induced pulmonary hypertension [J]. Arterioscler Thromb Vasc Biol, 2005, 25 (11) : 2335 -2342.
  • 10Yao J, Xiong M, Tang B, et al. Simvestatin attenuates pulmonary vascular remodelling by down - regadating matrix metalloproteinase - 1 and -9 expression in a carotid artery -jugular vein shuntpulmonary hypertansion model in rats [J]. Eur J Cardiothorac Surg, 2012, 42 (5): e121-127.

二级参考文献8

  • 1Rubin LJ. Therapy of pulmonary hypertension : the evolution from vasodilators to antiproliferative agents. Am J Respir Crit Care Med, 2002,166 : 1308-1309.
  • 2Martin KB, Klinger JR, Rounds SI. Pulmonary arterial hypertension: new insights and new hope. Respirology,2006,11: 6-17.
  • 3Nishimura T, Faul JL, Berry GJ, et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med, 2002, 166:1403-1408.
  • 4Lee JH,Lee DS, Kim EK, et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med, 2005, 172:987-993.
  • 5Girgis RE, Li D, Zhan X, et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol, 2003,285 : H938-H945.
  • 6Glorioso N, Triffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary percholesterolemia. Hypertension, 1999, 34 : 1281-1286.
  • 7Kandoussi A, Martin F, Hazzan M, et al. HMG-CoA reductase inhibition and PPAR-alpha activation both inhibit cyclosporin A induced endothelin-1 secretion in cultured endothelial cells. Clin Sci (Lond), 2002, 103 Suppl 48:81S-83S.
  • 8Kao PN. Simvastatin treatment of pulmonary hypertension: an observational series. Chest, 2005, 127:1446-1452.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部